A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)
Condition: Myelodysplastic Syndrome; Multiple Myeloma; Hodgkin Lymphoma; Non-Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Primary Mediastinal B-Cell Lymphoma
MeSH terms: Lymphoma; Multiple Myeloma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Myelodysplastic Syndromes
Intervention: Pembrolizumab; Lenalidomide 20 mg; Lenalidomide 25 mg
Intervention description: IV infusion; oral capsule; oral capsule
Intervention MeSH terms: Pembrolizumab; Lenalidomide
Phase: Phase 1
Study type: Interventional
Primary purpose: Treatment
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 197.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: PD1; PD-1; PDL1; PD-L1

Summary:

      The purpose of this trial is to evaluate the safety, tolerability, and efficacy of
      pembrolizumab (MK-3475, KEYTRUDA®) and pembrolizumab in combination with lenalidomide (Cohort
      5 only) in hematologic malignancies. The primary study hypotheses are that treatment with
      pembrolizumab will result in a clinically meaningful improvement in Objective Response Rate
      (ORR) or Complete Remission Rate (CRR).

      The study includes an initial dose determination to establish the recommended phase 2 dose
      (RP2D) of lenalidomide given in combination with pembrolizumab in Cohort 5.

      With Protocol Amendment 08, enrollment in the Multiple Myeloma arm (Cohort 2) has been
      completed and no further enrollment will be allowed and enrollment in the Non-Hodgkin
      Lymphoma Diffuse Large B Cell Lymphoma arm (Cohort 5) has been discontinued and no further
      enrollment will be allowed.
    

Eligibility criteria:

        Inclusion criteria:

          -  Has confirmed diagnosis of relapse or refractory Multiple Myeloma (enrollment
             completed), Primary mediastinal Large B cell Lymphoma, non-Hodgkin lymphoma (NHL),
             Follicular Lymphoma, Diffuse Large B cell lymphoma (enrollment discontinued), Hodgkin
             lymphoma or Myelodysplastic syndrome (enrollment completed).

          -  Has measurable disease

          -  Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
             Performance Scale

          -  Demonstrates adequate organ function

          -  Prior therapy criteria must be met

          -  Female participants of childbearing potential and male participants must agree to use
             an adequate method of contraception starting with the first dose of study therapy
             through 120 days after the last dose of study therapy

          -  Female participants of childbearing potential should have a negative urine or serum
             pregnancy test within 72 hours prior to receiving the first dose of study therapy

        Exclusion Criteria:

          -  Is currently participating in and receiving study therapy or has participated in a
             study of an investigational agent or used an investigational device within 4 weeks of
             the first dose of study therapy

          -  Has undergone prior allogeneic hematopoietic stem cell transplantation within the last
             5 years, has received a live vaccine within 30 days of planned start of study therapy,
             has received prior chemotherapy, targeted small molecule therapy, or radiation therapy
             within 2 weeks prior to study Day 1, received a monoclonal antibody within 4 weeks
             prior to study Day 1 or has not recovered from adverse events due to a previously
             administered agent

          -  Has known clinically active central nervous system (CNS) involvement

          -  Has a history of (non-infectious) pneumonitis that required steroids or current
             pneumonitis

          -  Has evidence of interstitial lung disease, active non-infectious pneumonitis, a known
             additional malignancy that is progressing or requires active treatment, an active
             infection requiring intravenous systemic therapy, an active autoimmune disease that
             has required systemic therapy, a known Human Immunodeficiency Virus (HIV), Hepatitis B
             (HBV), or Hepatitis C (HCV) infection

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the study starting with the pre-screening or screening visit
             through 120 days after the last dose of study therapy

          -  Has received prior therapy with an anti-programmed cell death 1 (anti-PD-1),
             anti-programmed cell death ligand 1 (anti-PD-L1), anti-PD-L2, anti-CD137, or
             anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including
             ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation
             or checkpoint pathways)

          -  Has known symptomatic congestive heart failure, unstable angina pectoris, or cardiac
             arrhythmia